PAREXEL and NTUH Enter Partnership
News Nov 30, 2012
PAREXEL International Corporation and the National Taiwan University Hospital (NTUH) have announced that they have established an alliance.
Under the agreement, PAREXEL and NTUH will collaborate to provide drug development services in Taiwan.
“Partnering with National Taiwan University Hospital further enhances our ability to meet the increasing demand from our clients to provide a full scope of Phase I-IV clinical trials in a rapidly growing market,” said Joe Avellone, M.D., Corporate Senior Vice President, Clinical Research Services, PAREXEL International.
Avellone continued, “The National Taiwan University Hospital is well-known and highly respected in Taiwan. We are pleased to have the opportunity to work together to advance our biopharmaceutical clients’ programs in the region and help them to compete more effectively in the global marketplace.”
“We are delighted to collaborate with PAREXEL, a world-leading biopharmaceutical services provider” said Ming-Fong Chen, M.D., Ph.D., Superintendent at National Taiwan University Hospital.
Chen continued, “PAREXEL has a wealth of experience in both local and global clinical development programs. This partnership will bring opportunities for both PAREXEL and NTUH to leverage our combined expertise in order to accelerate clinical development programs in Taiwan and meet patients’ need for more effective treatments.”
The alliance will drive greater efficiency for biopharmaceutical sponsors worldwide.
As a center of excellence for clinical trials in Taiwan and the Asia-Pacific region, the National Taiwan University Hospital is ideally positioned to support PAREXEL in delivering a superior clinical development service to local and global biopharmaceutical companies.
The combined experience and development expertise of the two organizations will help to create innovative solutions for biopharmaceutical companies looking to develop or market their products within this important region.
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
CBD Significantly Reduces Seizures in Patients with Severe Form of EpilepsyNews
Large-scale clinical trial finds cannabidiol can dramatically reduce the number of dangerous seizures in patients with a severe form of epilepsy called Lennox–Gastaut syndrome.
New Approach to Cancer Research Aims to Accelerate Studies and Reduce CostNews
A new model for improving how clinical trials are developed and conducted by bringing together academic cancer experts and pharmaceutical companies is being tested by research experts at The University of Texas MD Anderson Cancer Center.READ MORE
Comments | 0 ADD COMMENT
World Congress on Bio-organic and Medicinal Chemistry
Nov 12 - Nov 13, 2018